vimarsana.com

Page 2 - ஆந்திரா பிரதேஷ் ஆரோக்கியம் துறை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Welcome To IANS Live - SCIENCE - Citing CCMB study, Andhra rules out N440K role in current Covid surge

Photo Credit: IANS IANSLive Amaravati, May 6 (IANS) Andhra Pradesh Health Department has stated that research data compiled by the Centre for Cellular and Molecular Biology (CCMB) so far, doesn t establish that N440K is a variant of interest, and is virulent. The clarification comes in the wake of widespread concerns over the role of this particular variant in the spread of covid in the state currently. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action.

Not established yet that N440K COVID-19 variant is very virulent: Andhra Health Department

Highlights The Andhra Health Department has cited the CCMB report to prove its claim Amaravati: Andhra Pradesh Health Department on Thursday stated that recent research has not established that N440K, being referred to as the Andhra Pradesh COVID-19 variant, is of significant interest and very virulent. The Health Department also cited research data compiled by the Centre for Cellular and Molecular Biology (CCMB) to prove its point. It said that the CCMB data so far doesn`t establish that The clarification comes in the wake of widespread concerns over the role of this particular variant in the spread of the

Govt s 45-lakh dose order comes as a booster shot for Covaxin

March 11, 2021 The total number of doses of Covaxin administered till February 9 was 3.03 lakh   -  PTI The total number of doses of Covaxin administered till February 9 was 3.03 lakh   -  PTI× DCGI panel seen scrapping ‘clinical trial mode’ condition for the Bharat Biotech vaccine, based on 81 per cent efficacy report The acceptance for Covaxin, the Covid-19 vaccine developed entirely by the Hyderabad-based Bharat Biotech, appears to be rising perhaps after Prime Minister Narendra Modi took it, on March 1. Even as an official source confirmed to BusinessLine on Tuesday that the Health Ministry has ordered for 45 lakh doses of Covaxin for delivery by March 16, in another significant development, an independent Subject Expert Committee of the Drugs Controller General of India (DCGI) is learnt to have recommended ending the “clinical trial mode” condition for the vaccine, based on interim clinical trials results which showed 81 per cent efficacy. A final decision

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.